Poseida Therapeutics, Inc. Accounts Receivable
Poseida Therapeutics, Inc. had Accounts Receivable of $14.75 million as of 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AccountsReceivableNetCurrent · last filed 2024-11-07
- 2024-09-30: Accounts Receivable, after Allowance for Credit Loss, Current $14.75M.
- 2024-06-30: Accounts Receivable, after Allowance for Credit Loss, Current $12.43M.
- 2024-03-31: Accounts Receivable, after Allowance for Credit Loss, Current $12.03M.
- 2023-12-31: Accounts Receivable, after Allowance for Credit Loss, Current $9.01M.
| Period end | Accounts Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2024-09-30 | $14.75M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $12.43M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $12.03M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $9.01M 10-Q · filed 2024-11-07 |
| 2023-09-30 | $8.67M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $11.91M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $8.44M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $9.09M 10-K · filed 2024-03-07 |
| 2022-09-30 | $38.47M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $232.00K 10-Q · filed 2022-08-11 |